| Nicotinate and nicotinamide metabolism |
1.46 |
5.24e-1 |
25/35 (71.43%) |
NMRK1;NT5C2;NT5E;...
|
| Taurine and hypotaurine metabolism |
1.45 |
4.83e-1 |
8/11 (72.73%) |
GAD1;CSAD;GGT5;...
|
| Fanconi anemia pathway |
1.43 |
4.96e-1 |
36/54 (66.67%) |
RPA3;FANCA;POLI;...
|
| Thyroid hormone synthesis |
1.34 |
6.07e-1 |
66/75 (88%) |
GNAS;ADCY1;ITPR1;...
|
| Proteasome |
1.33 |
5.76e-1 |
44/46 (95.65%) |
PSMB9;PSMB3;PSME2;...
|
| Complement and coagulation cascades |
1.32 |
5.78e-1 |
76/85 (89.41%) |
C7;C5;CFB;...
|
| Prion disease |
1.31 |
5.71e-1 |
209/273 (76.56%) |
NCAM1;CAV2;TUBB;...
|
| Type I diabetes mellitus |
1.31 |
5.42e-1 |
38/43 (88.37%) |
GAD1;ICA1;HLA-DMB;...
|
| Basal transcription factors |
1.30 |
5.76e-1 |
37/45 (82.22%) |
GTF2I;MNAT1;TAF12;...
|
| Ovarian steroidogenesis |
1.30 |
5.46e-1 |
41/51 (80.39%) |
GNAS;ADCY1;STAR;...
|
| Amyotrophic lateral sclerosis |
1.27 |
6.04e-1 |
267/364 (73.35%) |
TUBB;TUBA1A;ANG;...
|
| Cocaine addiction |
1.27 |
5.96e-1 |
42/49 (85.71%) |
GNAS;GRIA2;FOSB;...
|
| Coronavirus disease |
1.26 |
5.92e-1 |
215/232 (92.67%) |
ISG15;AGTR1;C7;...
|
| Ubiquinone and other terpenoid-quinone biosynthesis |
1.26 |
5.70e-1 |
9/11 (81.82%) |
VKORC1;COQ2;NQO1;...
|
| Estrogen signaling pathway |
1.26 |
5.57e-1 |
119/137 (86.86%) |
KRT19;GNAS;ADCY1;...
|
| Insulin secretion |
1.24 |
5.90e-1 |
75/86 (87.21%) |
GNAS;ADCY1;SNAP25;...
|
| Amphetamine addiction |
1.24 |
5.71e-1 |
57/69 (82.61%) |
GNAS;GRIA2;FOSB;...
|
| Other glycan degradation |
1.23 |
5.65e-1 |
13/18 (72.22%) |
MAN2B2;FUCA1;NEU1;...
|
| Morphine addiction |
1.23 |
5.73e-1 |
80/91 (87.91%) |
GNAS;ADCY1;GNG11;...
|
| Parkinson disease |
1.22 |
5.76e-1 |
176/249 (70.68%) |
GNAS;UCHL1;TUBB;...
|
| Glutamatergic synapse |
1.21 |
5.99e-1 |
97/114 (85.09%) |
GNAS;ADCY1;GRIA2;...
|
| Metabolism of xenobiotics by cytochrome P450 |
1.21 |
5.86e-1 |
49/77 (63.64%) |
CYP1A1;MGST3;CYP2E1;...
|
| RIG-I-like receptor signaling pathway |
1.21 |
5.73e-1 |
64/70 (91.43%) |
ISG15;CXCL8;RNF125;...
|
| Glutathione metabolism |
1.20 |
5.70e-1 |
43/57 (75.44%) |
MGST3;RRM2;G6PD;...
|
| Graft-versus-host disease |
1.19 |
5.84e-1 |
32/42 (76.19%) |
HLA-DMB;HLA-B;HLA-F;...
|
| Vibrio cholerae infection |
1.19 |
5.73e-1 |
44/50 (88%) |
GNAS;ACTB;SEC61G;...
|
| Retrograde endocannabinoid signaling |
1.18 |
5.83e-1 |
118/148 (79.73%) |
ABHD6;ADCY1;GRIA2;...
|
| Primary bile acid biosynthesis |
1.18 |
5.72e-1 |
15/17 (88.24%) |
SLC27A5;HSD17B4;BAAT;...
|
| Selenocompound metabolism |
1.18 |
5.74e-1 |
11/17 (64.71%) |
PAPSS2;CTH;TXNRD3;...
|
| Mismatch repair |
1.16 |
6.04e-1 |
22/23 (95.65%) |
RPA3;MSH2;SSBP1;...
|
| Central carbon metabolism in cancer |
-1.26 |
6.33e-1 |
67/70 (95.71%) |
MET;MYC;PDHA1;...
|
| Ubiquitin mediated proteolysis |
-1.27 |
6.18e-1 |
87/140 (62.14%) |
RHOBTB2;TRAF6;TRIM37;...
|
| Insulin signaling pathway |
-1.27 |
6.32e-1 |
121/137 (88.32%) |
PRKAR2A;PCK2;EXOC7;...
|
| JAK-STAT signaling pathway |
-1.28 |
6.27e-1 |
146/162 (90.12%) |
GRB2;IL12RB2;PRL;...
|
| Sphingolipid signaling pathway |
-1.28 |
6.25e-1 |
106/119 (89.08%) |
PRKCZ;AKT1;RELA;...
|
| Phenylalanine metabolism |
-1.29 |
6.23e-1 |
14/17 (82.35%) |
HPD;ALDH3B1;PAH;...
|
| Inflammatory bowel disease |
-1.29 |
6.11e-1 |
58/65 (89.23%) |
TLR2;IL12B;IL4R;...
|
| Systemic lupus erythematosus |
-1.30 |
6.28e-1 |
45/135 (33.33%) |
C1QB;ACTN4;CD86;...
|
| Axon guidance |
-1.30 |
6.22e-1 |
151/182 (82.97%) |
ARHGEF12;ABL1;PLCG1;...
|
| Fatty acid degradation |
-1.31 |
5.97e-1 |
40/43 (93.02%) |
ACOX3;ACSL5;ADH5;...
|
| Hippo signaling pathway |
-1.32 |
6.16e-1 |
120/186 (64.52%) |
FZD9;BMPR2;FRMD1;...
|
| Ferroptosis |
-1.32 |
6.21e-1 |
36/41 (87.8%) |
SAT1;ACSL5;SLC11A2;...
|
| Gastric acid secretion |
-1.33 |
6.26e-1 |
63/76 (82.89%) |
ATP1B2;ATP1A2;ITPR3;...
|
| Prostate cancer |
-1.34 |
6.09e-1 |
93/97 (95.88%) |
HSP90AA1;AKT1;RELA;...
|
| HIF-1 signaling pathway |
-1.34 |
6.30e-1 |
105/109 (96.33%) |
EDN1;NOS3;IFNGR2;...
|
| Porphyrin and chlorophyll metabolism |
-1.34 |
6.34e-1 |
23/43 (53.49%) |
UGT2A3;PPOX;HMOX2;...
|
| Staphylococcus aureus infection |
-1.36 |
6.41e-1 |
72/95 (75.79%) |
FPR2;C1QB;FPR3;...
|
| TGF-beta signaling pathway |
-1.37 |
6.19e-1 |
81/94 (86.17%) |
GDF5;BMPR1B;THBS1;...
|
| TNF signaling pathway |
-1.41 |
6.20e-1 |
103/112 (91.96%) |
CREB3L1;MAPK3;TAB2;...
|
| Cytokine-cytokine receptor interaction |
-1.51 |
3.27e-1 |
246/295 (83.39%) |
CD27;IL36A;IL10RB;...
|
| Acute myeloid leukemia |
-1.55 |
2.51e-1 |
66/67 (98.51%) |
RAF1;BRAF;PER2;...
|
| Viral protein interaction with cytokine and cytokine re... |
-1.57 |
2.33e-1 |
84/100 (84%) |
CXCL13;CXCL3;CCR9;...
|
| Histidine metabolism |
-1.58 |
2.43e-1 |
16/22 (72.73%) |
ALDH3B1;CNDP2;MAOA;...
|
| Proximal tubule bicarbonate reclamation |
-1.58 |
2.72e-1 |
21/23 (91.3%) |
ATP1B2;ATP1A2;AQP1;...
|
| Protein digestion and absorption |
-1.61 |
2.34e-1 |
78/103 (75.73%) |
COL21A1;SLC15A1;COL5A3;...
|
| Pertussis |
-1.63 |
2.24e-1 |
64/76 (84.21%) |
C1QB;MAPK1;ITGA5;...
|
| AGE-RAGE signaling pathway in diabetic complications |
-1.66 |
2.20e-1 |
97/100 (97%) |
PRKCZ;AKT1;COL1A1;...
|
| Nitrogen metabolism |
-1.67 |
2.78e-1 |
16/17 (94.12%) |
CA9;CA3;CA12;...
|
| Tuberculosis |
-1.69 |
3.04e-1 |
159/180 (88.33%) |
CD74;ATP6V0A4;ATP6V0A2;...
|
| Collecting duct acid secretion |
-1.80 |
2.26e-1 |
22/27 (81.48%) |
TCIRG1;ATP4B;ATP6V1G1;...
|
